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Background: An ageing population increases demand on health and social care. New approaches are needed to
shift care from hospital to community and general practice. A predictive risk stratification tool (Prism) has been
developed for general practice that estimates risk of an emergency hospital admission in the following year. We
present a protocol for the evaluation of Prism.
Methods/Design: We will undertake a mixed methods progressive cluster-randomised trial. Practices begin as
controls, delivering usual care without Prism. Practices will receive Prism and training randomly, and thereafter be
able to use Prism with clinical and technical support. We will compare costs, processes of care, satisfaction and
patient outcomes at baseline, 6 and 18 months, using routine data and postal questionnaires. We will assess
technical performance by comparing predicted against actual emergency admissions. Focus groups and interviews
will be undertaken to understand how Prism is perceived and adopted by practitioners and policy makers. We will
model data using generalised linear models and survival analysis techniques to determine whether any differences
exist between intervention and control groups. We will take account of covariates and explanatory factors. In the
economic evaluation we will carry out a cost-effectiveness analysis to examine incremental cost per emergency
admission to hospital avoided and will examine costs versus changes in primary and secondary outcomes in a
cost-consequence analysis. We will also examine changes in quality of life of patients across the risk spectrum. We
will record and transcribe focus groups and interviews and analyse them thematically. We have received full ethical
and R&D approvals for the study and Information Governance Review Panel (IGRP) permission for the use of routine
data. We will comply with the CONSORT guidelines and will disseminate the findings at national and international
conferences and in peer-reviewed journals.
Discussion: The proposed study will provide information on costs and effects of Prism; how it is used in practice,
barriers and facilitators to its implementation; and its perceived value in supporting the management of patients
with and at risk of developing chronic conditions.
Trial registration: Controlled Clinical Trials ISRCTN no. ISRCTN55538212.
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An ageing population and the associated increasing num-
bers of people with chronic conditions are placing unpre-
cedented demands on health and social care services, both
nationally and internationally [1-3]. New approaches to
the management of chronic conditions are needed to shift
the balance of care from the acute sector to primary and
community sectors [4-6] through enhanced local services.
Clinical prediction models or risk scores are designed
to predict a patient’s risk of having or developing a spe-
cified outcome or disease [7]. They use clinical findings
(including medical history, drug use and test results) to
make a diagnosis or predict an outcome [8]. As doctors ei-
ther implicitly or explicitly use multiple predictors to assess
a patient’s prognosis, multivariable approaches to the de-
sign of prediction models are more effective than single
predictors [9]. Such prediction models are intended to help
clinicians make better decisions by providing more objec-
tive estimates of probability as a supplement to other clin-
ical information [9,10].
In 2008 the Wales Audit Office (WAO), UK, reported
that NHS Wales was not providing services that fully sup-
ported the effective management of chronic conditions
[11]. The report highlighted that 68% of admissions for
chronic conditions were unplanned, and nearly 40% of ad-
missions resulted in stays of less than 2 days. The new na-
tional policy for chronic conditions management in Wales
is seeking to avoid the deterioration of existing chronic
conditions by implementing a proactive, planned, inte-
grated and generic approach to chronic conditions man-
agement across all sectors [6,12,13].
Three major research tasks have been identified that
need to be completed before predictive risk tools can be
routinely used in clinical practice: developing the prognos-
tic model, validating its mathematical performance and
evaluating its clinical performance [9,14-16]. The third task
related to evaluating clinical performance is crucial, and the
effect of a prognostic model on clinical behaviour and pa-
tient outcomes should be evaluated separately from the first
two tasks [14]. While the number of prediction models is
increasing, few have been validated [8] and evidence about
their effects on patient care is limited. Reilly commented
that, “without evaluation, clinicians cannot know whether
using a prediction rule will be beneficial or harmful” [8].
Moons et al. suggested that formal validation and evalu-
ation studies, ideally with random allocation of patients to
intervention and control groups, can provide an opportun-
ity to study factors that may affect the implementation of a
prognostic model in daily care, including the acceptability
and ease of use of the prognostic model to clinicians [14].
Although condition-specific risk prediction tools have
been successfully developed and applied to conditions
such as diabetes and coronary heart disease [17,18], there
is less evidence regarding generic population-based tools.Predictive models, such as Patients at Risk of Readmission
(PARR) and Scottish Patients At Risk of Readmission and
Admission (SPARRA), have been used successfully in
the UK National Health Service (NHS) to stratify patients
into risk levels [19,20]. The models used in England and
Scotland focussed only on those at most risk – on patients
over 65 years in Scotland and on the sickest 1% or 2% in
England. Steps to include the whole population were later
included in the English Combined Predictive Model and
are now being taken in Wales through the development of
a predictive risk stratification model (Prism) [21]. Prism
calculates a risk score of between 0 (no risk) and 100 (very
high risk), based on patient demographics and data from
primary and secondary care record systems. Patients
are stratified into four levels based on their individual
risk of having an emergency admission to hospital dur-
ing the following year. This reflects the Welsh Chronic
Conditions Management policy focus to prevent dis-
ease onset and deterioration across the population [6].
The performance of Prism appears comparable to or
better than the English model [21] and an independent
pilot evaluation [22] has indicated potential for impact.
However, many practical questions remain about how
it will be adopted and used by service providers for
each risk stratum [23].
Although stratification will not in itself lead to im-
provements in service delivery, it aims to stimulate the
planning and targeting of care. Thus it is intended to influ-
ence health care delivery and ultimately patient outcomes.
Recent policy documents in the UK and internationally
have generated expectations that, in future, health com-
munities will routinely stratify their populations according
to risk of hospital admission [1,2,6,24,25]. To inform fu-
ture policy and practice we designed a prospective evalu-
ation of the implementation of Prism and present the
study protocol in this article.
Study aim
To describe the processes of introducing a predictive risk
stratification model (Prism) in Wales and to estimate its
effects on the delivery of care, patient satisfaction, quality
of life and resources used.
Objectives
1) Measure changes in the profile of services delivered
to patients across the spectrum of risk, focussing on
emergency admissions to hospital.
2) Estimate the costs of implementing Prism and costs
or savings associated with resulting changes in the
utilisation of health and social care resources.
3) Assess the cost effectiveness of Prism by estimating
cost per quality-adjusted life year based on changes
in patient health outcomes.
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how it is understood, communicated, adopted and
used by practitioners, managers, local
commissioners and policy makers.
5) Assess the effect of Prism on patient satisfaction.
6) Assess the technical performance of Prism.
Design
We will undertake a mixed-methods progressive cluster-
randomised trial with a quantitative evaluation sited with-
in an area in southwest Wales and qualitative fieldwork
across the whole of Wales. The main trial site, Abertawe
Bro Morgannwg University Health Board (ABM UHB), is
the second largest of seven health boards in Wales, serving
around 600,000 people. It is divided into 11 GP practice
clusters, within which there are 77 general practices. We
will invite each of these practices to participate, with a tar-
get of 30–40 recruited practices.
The study fulfils the last of the three major steps (that
of evaluating the clinical performance), in researching
multivariable prognostic models identified by the recent
series in the British Medical Journal [9].
So that all participating practices have the opportunity
to implement and use the Prism tool during the study
period, we will use a progressive cluster-randomised trial
design (randomised multiple interrupted time-series or
stepped wedge design) [26-28] (see Figure 1).Figure 1 Randomised multiple interrupted time-series study design oAll participating practices will begin as control prac-
tices without Prism; receive the Prism package and train-
ing; and thereafter be able to use Prism with clinical and
technical support. Randomisation of practice clusters will
be stratified by locality. The West Wales Organisation for
Rigorous Trials in Health (WWORTH) will produce a
random allocation schedule for the trial. Allocations will
be concealed from the practices until 6 weeks prior to re-
ceiving the intervention. They will then be notified of the
timescale for receipt of the intervention by telephone and
email and training will be arranged before implementation
of the intervention.
As the trial progresses, the number of intervention prac-
tices will increase and the number of control practices will
fall. This design protects against many sources of bias, in-
cluding inherent differences in study sites, contamination
between practices, arbitrary changes in health policy and
the ‘resentful demoralisation’ of controls deprived of the
intervention.
Prism
Prism is a web-based predictive risk tool commissioned
by the Welsh Government that stratifies a General Prac-
tice population into four levels based on the individual
risk of an emergency admission to hospital in the follow-
ing 12 months. Prism was developed and checked using
300,000 (10% of the Welsh population) anonymised GPverview.
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highest predictive power were selected. The variables
used to develop Prism were drawn from routinely avail-
able data on inpatient, outpatient and primary care epi-
sodes and from the Welsh Index of Multiple Deprivation
(http://wales.gov.uk/topics/statistics/theme/wimd/wimds
tatement/;jsessionid=36B68DFE653760993E3E03966D776
0B8?lang=en), which includes data on employment, in-
come, housing, environment, education and health. To
enable GP practices, individually or collectively, to plan
workforce and resource allocation, each stratum repre-
sents a variable percentage of the practice population
(which can be changed at the practice level depending
on how they want to look at their own population data)
with the top stratum (level 4) of patients being at highest
risk of an emergency admission in the following year. The
theoretical basis of the model is that patients in each of
the four strata need very different targeted resources: level
4 requires individual case management, level 3 requires
disease management on a population basis, level 2 requires
supported self-care and level 1 needs prevention of illness
and promotion of health and wellbeing.Intervention
The intervention comprises: Prism software, practice-based
training; clinical support through two locally appointed ‘GP
champions’, a telephone ‘help desk’ during working hours
and a user-friendly handbook of guidance on using Prism
including links to available Community Resource Teams
that work at the locality level to provide multidisciplinary
health and social care approaches to the assessment and
management of more complex cases within the ageing
community [29] (see Figure 2).Prism software Installed on PC
the practice be
Practice based training A one-hour se
Prism lead GP
interested pra
GP champions Two local GPs
 to deliver clin
 in relation to P
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Figure 2 Components of the intervention.Outcomes
Following Prism activation, we will compare between
intervention and control groups:
Primary outcome
Number of emergency admissions per patient to hospital
and time to first admission.
Secondary outcomes
Primary care service use—GP practice events/event days.
Accident and emergency attendances.
Community care service use.
Secondary care inpatient and outpatient episodes (in-
cluding length of stays).
NHS implementation costs.
Number of Prism users.
Pattern (including frequency) of Prism use.
Patient satisfaction.
Predicted emergency admissions.
Health-related quality of life (SF-12).
We will also explore in detail within the intervention
group and at other sites:
 Technical performance of the Prism tool—predicted
compared to actual emergency admissions to hospital.
 Practitioner, commissioner and policy maker views
about Prism implementation, adoption and effects.
Methods/Design
To meet study objectives we will use anonymised linked
routine data relating to processes of care for all patients
registered at participating practices and will send postal
questionnaires to a sample of patients at random, weighteds in each practice and then activated as  
gins the intervention period.  
ssion delivered in the practice to the  
, practice manager and any other  
ctice staff by a GP champion.
 employed for two sessions per month 
ical support to practices   
rism use.
port provided within office hours by 
formatics Service to deal with enquiries 
l aspects of using Prism.
er-friendly handbook explaining how to 
ess Prism, demonstrating the range of 
lable in Prism, and giving suggestions for 
ithin the practice. 
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In addition, we will carry out focus groups and one-to-one
interviews with service providers, commissioners, man-
agers and policy makers. Figure 1 illustrates the continuous
process of the trial and illustrates at what points during the
trial we will collect data using the defined methods.
Data collection and sources
Table 1 outlines the various data sources that will be col-
lected, at what time points within the study these will be
collected and how the data sources will used to answer
our study objectives.
Anonymised linked data
We will use routine data from the Secure Anonymised
Information Linkage (SAIL) databank [30] to compare
services delivered to patients (emergency, acute, primary,
community and social care) across the spectrum of risk
between intervention and control practices. SAIL includes
routine Welsh hospital data such as emergency admissions
(Emergency Department Data Set; EDDS), secondary care
(Patient Episode Database for Wales, PEDW) and GP
practice data. We will run the Prism algorithm within the
SAIL databank to generate risk scores linked to health ser-
vice usage data for all study patients who do not dissent.
Postal questionnaires
We will send postal questionnaires to sampled patients at
three points—baseline, 6 and 18 months after Prism imple-
mentation in the first study practice. The questionnaire is
made up of three validated tools: the adapted Client Service
Receipt Inventory, CRSI [31] (to capture individual health
service usage data), the Quality of Care Monitor (QCM)
[32] and the SF-12 [33] to measure patient outcomes. We
will recruit random samples each of 800 patients at each
time point to complete the questionnaires (i.e. a minimum
of 20 per practice based on 40 participating practices) stra-
tified across the spectrum of risk (see Table 2).
As higher risk patients are likely to receive more in-
tensive resources, we shall oversample at the higher risk
levels (3 and 4). Our sampling approach will also take
account of an expected reduced response rate from higher
risk patients—many of whom will have multiple chronic
conditions. Practice patients less than 18 or greater than
100 years of age, recently deceased or moved will be ex-
cluded from the sampling frame. Random sampling of the
patient population will be carried out on the anonymous
Prism data by the Prism data providers (NHS Wales In-
formatics Service; NWIS). The selected patients will only
be identifiable at practice level. Once selected, the GPs
from participating practices will assess the suitability of the
patients to receive the Prismatic questionnaire by screen-
ing the list of sampled patients. Examples of reasons for
patient exclusion will include patients that lack capacity,those who do not have support to help them complete the
questionnaire and patients who may be caused distress by
completing the questionnaire. Questionnaires packs (letter
from GP, information sheet, consent form, questionnaire,
postage-paid envelope) will be sent directly from partici-
pating practices to selected patients. We will gain consent
from patients to participate in the trial. Completed ques-
tionnaires and consent forms will be returned directly to
the study team. Only following consent will the study team
gain access to patient demographic information (name,
date of birth, address, etc.). The practices will send out a
second questionnaire pack to those patients who have not
responded to the first if no reply has been received after
2 weeks.
We will adopt the same basic design for each of the two
later surveys. Recruited baseline practice patients will be
screened again at the later time points by their GPs to en-
sure that they are still suitable to participate and that none
of the participants have died. We will re-sample the GP
practice population to replace any losses and to ensure
that we have the same number of patients from each prac-
tice at these later time points. We will stratify the replace-
ment sample by age, sex and risk stratum to match those
removed from the sample.
Focus groups and interviews
We will collect qualitative data from GPs and practice staff
at baseline and post implementation to explore current
practice in chronic conditions management and processes
of change initiated by Prism. Questions will address atti-
tudes, expectations and experience relating to predictive
risk stratification and specifically the Prism tool, including
barriers and facilitators to use.
At baseline, before Prism is activated in the first inter-
vention practices we will conduct four focus groups with
staff from general practices, two in one locality where
geography suggests a natural division and one each in the
other two locality areas. GPs unable to take part in a focus
group will be offered an interview by telephone or face-to-
face. We will also conduct focus groups with area-wide se-
nior managers and community-based practitioners, one at
baseline and one at the end of the intervention period.
Focus groups will allow exploration of different views and
experiences and encourage group interaction [34].
In order to gain more in-depth information about adop-
tion and use and perceptions of effectiveness, we will
undertake one-to-one interviews with staff following Prism
implementation. We will purposively sample half the par-
ticipating practices (20, based on 40 participating prac-
tices) and interview Prism user(s) at two time points—3
and 9 months after Prism implementation—face-to-face or
by telephone. This will allow us to explore changes in
adoption and use over time. We will administer a ques-
tionnaire to the other half of participating practices, also at
Table 1 Overview of methods employed in the study, matched to study objectives
Objective Data source Sample Collection time
1. Measure changes in the profile of services
delivered to patients across the spectrum of risk,
focussing on emergency admissions to hospital
Anonymised routine linked data
(including Prism data)




Services Receipt Inventory (CSRI)
Random sample of patients from
participating practices




2. Estimate the costs of implementing Prism and
costs of resulting changes in the utilisation of
health and social care resources
Questionnaire data: Client Services
Receipt Inventory (CSRI); SF12
Random sample of patients from





Structured telephone interviews Prism users from all participating
practices (n = up to 40)
18 months
3. Assess the cost effectiveness of Prism by
estimating cost per quality-adjusted life year
based on changes in patient health outcomes
Questionnaire data: SF12 Random sample of patients from





Structured telephone interviews Prism users from all participating practices 18 months
4. Describe processes of change associated with
Prism: how it is understood, communicated,
adopted and used by practitioners, managers,
local commissioners and policy makers
Focus groups GPs, practice nurses and managers from
participating practices (n = 4); local health
services managers and community staff
managers (n = 1)
Baseline
Interviews GPs from participating practices who
are unable to attend FGs (n = 12);
Baseline
health board managers from sites not
participating in main study (n = 6); policy
makers and national health service
managers (n = 5)
Interviews Prism users from half of all participating
practices, purposively sampled
3 months and 9
months after going live
Questionnaire Prism users from remaining half of all
participating practices
3 months and 9
months after going live
Focus group Local health services managers and
community staff managers (n = 1)
18 months
Interviews Health service managers from ABMU (n = 3) 18 months
Structured telephone interviews Prism users from all participating
practices (n = up to 40)
18 months
5. Assess the effect of Prism on patient satisfaction Questionnaire data: Quality
of Care Monitor
Random sample of patients from










Anonymised routine linked data Routine health data Baseline
6 months
18 months
Structured telephone interviews Prism users from all participating
practices (up to 40)
18 months
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Sample (number of patients)
for screening in each practice
Level 4 (50 to 100) 20 15
Level 3 (20 to 50) 50 35
Level 2 (10 to 20) 15 10
Level 1 (0 to 10) 15 10
Total sample 100 70
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tionnaire responses will inform our interviews and enable
us to see divergence or concurrence across all participating
practices.
We will also interview three senior managers within
ABM UHB during implementation to explore area-wide
issues related to patient management and the effects of
Prism in GP practices. Interviews will allow us to ex-
plore in detail respondents’ views about Prism and the
use of the tool in their area [35].
In order to gain political, managerial and historical
perspectives on the development and implementation of
Prism, we will undertake further interviews with man-
agers, policy makers and health services commissioners
(n = 5) with an all-Wales perspective, face to face or by
telephone at baseline. In addition, we will carry out in-
terviews with respondents from non-participating Health
Board sites across Wales (n = 6) in order to examine
their experience of Prism and their perspective on its
role and potential.
Sample size and power
The total of 2,400 respondents will allow us to detect
changes between current intervention and control sites
in resource use across the spectrum of risk. For example
we shall have 80% power when using a 5% significance
level to detect changes of 15% in the proportion of pa-
tients at a defined risk receiving a specified resource,
such as case management or support to quit smoking.
Analysis
The study will comply with the Statistics Standard Oper-
ating Procedure (SOP) of the West Wales Organisation
for Rigorous Trials in Health (WWORTH), the clinical
trials unit at Swansea University. Primary analysis will be
by treatment allocated. The primary outcomes are num-
ber of emergency admissions per patient and the time to
first event (namely emergency admission). The first of
these is a count variable and hence can be modelled using
a generalised linear model incorporating an appropriate
discrete distribution; the second is a measurement vari-
able, subject to right-censoring, and can be modelled using
appropriate survival analysis techniques including Cox’sproportional hazards models. Both methods take account
of covariates and explanatory factors (including whether
the participant’s practice has yet adopted Prism or not);
neither methodology makes any normality assumptions.
The list of potential explanatory factors and covariates in-
cludes baseline observations, time-varying covariates and
days at risk.
The technical performance of the Prism tool will be
assessed by analysing the data at baseline and across the
control phase. We will plot the proportion of patients
who experience hospital admissions against the pro-
spective Prism risk score and calculate sensitivity, speci-
ficity, positive and negative predictive values. We will
control for any confounding effects of Prism implemen-
tation during the analysis period by fitting a binary par-
ameter showing whether practices have adopted Prism
yet or not.
The perspective of NHS Wales and personal social ser-
vices will be adopted for the health economic analysis.
The costs of implementing Prism in intervention and
control sites will be derived from interviews with GP
practice staff and with members of the main trial team
(e.g. training resources). The costs associated with resulting
changes in care processes will be derived from routine data
collected by the Prism system from SAIL and by patient-
reported information collected by the CSRI questionnaire.
Costs will be presented in a tabular format reporting the
estimated resource quantities and unit costs attached. The
estimation of the size of the differences (means and stand-
ard deviations) in resource use between intervention and
control sites within each of the four risk strata and overall
will be calculated and valued in monetary terms using pub-
lished unit costs (with year of reported cost reported) [36].
The primary health economic analysis will be the calcula-
tion of the incremental cost per emergency admission
avoided in a cost-effectiveness analysis and will produce a
tabular representation of costs versus changes in primary
and secondary outcomes in a cost-consequences analysis.
The incremental cost per quality-adjusted life year (cost/
QALY) will be calculated in a cost-utility analysis using SF-
6D utility scores derived from SF-12 patient questionnaire
data. A series of univariate sensitivity analyses will be car-
ried out to determine the extent to which changes in the
basic assumptions of the economic analysis affect the in-
cremental cost-effectiveness ratio.
We will record and transcribe focus groups and inter-
views and analyse them thematically. This is a systematic
and transparent method of analysis that generates themes
from the explicit and implicit ideas contained in the ori-
ginal accounts of participants. One researcher will lead
the analysis with two others independently supporting key
stages of coding, generating themes and interpretation
and encouraging a critical stance to test and confirm find-
ings [35,37,38].
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The trial has been adopted by WWORTH and we will
adhere to all relevant WWORTH standard operating
procedures (SOPs) in the conduct, management and moni-
toring of the study. The strategic management of the trial
will be the responsibility of a Research Management Group
(RMG) meeting quarterly and comprising the Chief Inves-
tigator, all co-applicants, all research staff, two service users
and two local participating General Practitioners. Oper-
ational management will be the responsibility of the Re-
search Team meeting every month and comprising the
researchers, clerical support, the Principal Investigator and
one of the co-applicants. HAH will be Research Manager
responsible for the operational management of the project
from day to day. The PI and Research Manager will ensure
adherence to the planned timescale and detailed plans for
data management and analysis. A data management task
and finish group will oversee all data management and
analysis issues. The WWORTH SOP on data management
will be used to develop a data management plan, outlining
details of data entry, coding, security and storage, in-
cluding any related processes to promote data quality.
An independent Trial Steering Committee (TSC) will pro-
vide overall supervision for the study and ensure the rigor-
ous conduct of the trial. It will meet twice a year and be
made up of an independent chair with an interest in emer-
gency care, an academic in primary care, a consultant in
public health, a statistician and two service users (with no
previous involvement in the trial). We will adopt the prin-
ciples outlined in WWORTH’s SOPs on Quality Assur-
ance and independent trial monitoring will be carried out
through WWORTH.Including service and research users
In accordance with the WWORTH Standard Operating
Procedure for Service User Inclusion [39], we have re-
cruited two service users who will actively participate
throughout the study as members of the Research Manage-
ment Group. They were recruited through SUCCESS (Ser-
vice Users with Chronic Conditions Encouraging Sensible
Solutions), a group of patients and carers involved in re-
search linked to the chronic conditions management policy
in Wales (http://www.invo.org.uk/posttypeconference/an-
alternative-success-model/) The two service user represen-
tatives contribute views from the wider SUCCESS group.Ethics and dissemination
The Multi-Centre Research Ethics (MREC) Committee for
Wales has given full ethical approval for the study (refer-
ence 10/MRE09/25). R&D permissions have been granted
across Wales. We have received Information Governance
Review Panel (IGRP) permission for use of the SAIL
databank. We will seek further approval for any proposedchanges to the trial design or conduct with the MREC and
relevant R&D committees via amendment reports.
We will comply with the CONSORT guidelines [40].
We will present study results at national and international
conferences and publish them in peer-reviewed and clin-
ical journals. We have produced a publication plan and
authorship agreement for dissemination of the study find-
ings. Only those individuals who fulfil the authorship cri-
teria will be included as authors on final publications.
Discussion
There is a lack of evidence regarding how well predictive
risk tools work in supporting the management of patients.
The proposed study will provide information on costs and
effects of Prism; how it is used in practice, barriers and fa-
cilitators to its implementation; and its perceived value in
supporting the management of patients with and at risk of
developing chronic conditions. These findings will have
UK and international relevance at a time of heightened
focus on chronic conditions management and predictive
modelling.
Trial status (August 2013)
The PRISMATIC trial is currently underway and we have
now recruited 32 General Practices across the AMB UHB
area to take part. Baseline qualitative data collection (staff
focus groups and interviews) were carried out between
October 2012 and January 2013. Baseline patient ques-
tionnaire distribution began in April 2013.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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